Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-09-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
Monthly Returns
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized/registered share capital, issued shares, share options, and confirmations related to securities issued by Yankuang Energy Group Company Limited. It includes tables of share capital balances, share options outstanding, and confirmations by a company director. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. It does not contain financial statements, earnings data, or management discussion of financial results. It is a regulatory filing reporting share capital and share issuance movements for a specific month (August 2022). The document is about share capital and share issuance movements but does not announce new share issues or capital changes per se, rather it reports monthly movements and confirmations. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS).
2022-09-06 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It details securities transactions by China International Capital Corporation Limited, including dates, nature of dealings, and prices. The document references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is related to insider or director dealings disclosures. It is not a full financial report, earnings release, or management discussion. It is specifically about personal share transactions by a connected party, which fits the definition of Director's Dealing filings.
2022-09-05 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It details a transaction involving the sale of shares by China International Capital Corporation Limited, including dates, number of shares, prices, and nature of dealings. The document references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is a regulatory disclosure related to insider or connected party share transactions. It does not contain financial statements, management discussion, or report content. It is not an announcement of a report publication but a specific insider dealing disclosure. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is short and focused solely on share dealings by a connected party, confirming the classification.
2022-09-02 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is related to insider or director share transactions. The content includes details of share purchases and sales by a connected party. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on share dealings, with no financial statements or other report content.
2022-09-01 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating insider or related party transactions. The content focuses on share transactions by a connected party, including purchase details and prices. There is no financial report, earnings data, or management discussion. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or connected parties.
2022-08-31 English
GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options to the chief executive officer and executive director under the company's post-IPO employee share option plan (ESOP). It details the number of options granted, vesting schedules, subscription price, and the requirement for shareholder approval at a general meeting. The content focuses on the issuance of share options as part of executive remuneration and capital structure changes. There is no financial statement, audit information, or detailed financial performance data. The document is not a full report but an announcement of a capital-related event (grant of options). Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length (8851 characters) and detailed content confirm it is not a brief notice or a simple regulatory filing but a substantive announcement about capital changes.
2022-08-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.